(Q43782280)

26 November 2017

Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection (English)

1 reference

26 November 2017

0 references

1 reference

1 reference

1 reference

Tsang SW

1

1 reference

26 November 2017

Chan HL

2

1 reference

26 November 2017

Leung NW

3

1 reference

26 November 2017

Chau TN

4

1 reference

26 November 2017

Lai ST

5

1 reference

26 November 2017

Chan FK

6

1 reference

26 November 2017

Sung JJ

7

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

Alimentary Pharmacology & Therapeutics

26 November 2017

1 reference

26 November 2017

15

1 reference

26 November 2017

11

1 reference

26 November 2017

1737-1744

1 reference

Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology

26 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01107.X

Clinical course of spontaneous reactivation of hepatitis B virus infection in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01107.X

Liver transplantation for acute hepatic failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01107.X

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01107.X

Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01107.X

Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01107.X

Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody-positive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01107.X

Early indicators of prognosis in fulminant hepatic failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01107.X

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01107.X

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01107.X

Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01107.X

Renal failure in fulminant hepatic failure and terminal cirrhosis: a comparison between incidence, types, and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01107.X

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01107.X

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01107.X

APPLICABILITY OF LIVING DONOR LIVER TRANSPLANTATION TO HIGH-URGENCY PATIENTS

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01107.X

10.1046/J.1365-2036.2001.01107.X

21 January 2018

Identifiers

DOI

1 reference

26 November 2017

1 reference